Is AN2 Therapeutics Stock a Good Investment?
AN2 Therapeutics Investment Advice | ANTX |
- Examine AN2 Therapeutics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research AN2 Therapeutics' leadership team and their track record. Good management can help AN2 Therapeutics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact AN2 Therapeutics' business and its evolving consumer preferences.
- Compare AN2 Therapeutics' performance and market position to its competitors. Analyze how AN2 Therapeutics is positioned in terms of product offerings, innovation, and market share.
- Check if AN2 Therapeutics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about AN2 Therapeutics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in AN2 Therapeutics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if AN2 Therapeutics is a good investment.
Sell | Buy |
Sell
Market Performance | Very Weak | Details | |
Volatility | Dangerous | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Not Available | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine AN2 Therapeutics Stock
Researching AN2 Therapeutics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 23.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 0.44. Some equities with similar Price to Book (P/B) outperform the market in the long run. AN2 Therapeutics recorded a loss per share of 1.51. The entity last dividend was issued on the 11th of January 2018.
To determine if AN2 Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding AN2 Therapeutics' research are outlined below:
| AN2 Therapeutics generated a negative expected return over the last 90 days | |
| AN2 Therapeutics has some characteristics of a very speculative penny stock | |
| AN2 Therapeutics has high historical volatility and very poor performance | |
| AN2 Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (51.32 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| AN2 Therapeutics currently holds about 113.39 M in cash with (49.26 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.84, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| AN2 Therapeutics has a poor financial position based on the latest SEC disclosures | |
| Roughly 23.0% of the company shares are held by company insiders |
AN2 Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in AN2 Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to AN2 Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 3rd of April 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 3rd of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
AN2 Therapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 31.99 M.Basic technical analysis of AN2 Stock
As of the 4th of August, AN2 Therapeutics owns the Variance of 9.13, market risk adjusted performance of 1.77, and Information Ratio of (0.07). AN2 Therapeutics technical analysis gives you the methodology to make use of past data patterns to determine a pattern that approximates the direction of the firm's future prices.AN2 Therapeutics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific AN2 Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on AN2 Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases AN2 Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
AN2 Therapeutics' Outstanding Corporate Bonds
AN2 Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. AN2 Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most AN2 bonds can be classified according to their maturity, which is the date when AN2 Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| AON P 8205 Corp BondUS037389AK90 | View | |
| AON P Corp BondUS037389BE22 | View | |
| AON P Corp BondUS037389BC65 | View | |
| AON P 45 Corp BondUS037389BB82 | View | |
| AON P 625 Corp BondUS037389AU72 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View |
Understand AN2 Therapeutics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing AN2 Therapeutics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | 1.77 | |||
| Mean Deviation | 1.99 | |||
| Coefficient Of Variation | (3,608) | |||
| Standard Deviation | 3.02 | |||
| Variance | 9.13 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.09) | |||
| Total Risk Alpha | (0.49) | |||
| Treynor Ratio | 1.76 | |||
| Maximum Drawdown | 20.22 | |||
| Value At Risk | (3.51) | |||
| Potential Upside | 3.77 | |||
| Skewness | (0.46) | |||
| Kurtosis | 5.21 |
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | 1.77 | |||
| Mean Deviation | 1.99 | |||
| Coefficient Of Variation | (3,608) | |||
| Standard Deviation | 3.02 | |||
| Variance | 9.13 | |||
| Information Ratio | (0.07) | |||
| Jensen Alpha | (0.09) | |||
| Total Risk Alpha | (0.49) | |||
| Treynor Ratio | 1.76 | |||
| Maximum Drawdown | 20.22 | |||
| Value At Risk | (3.51) | |||
| Potential Upside | 3.77 | |||
| Skewness | (0.46) | |||
| Kurtosis | 5.21 |
Consider AN2 Therapeutics' intraday indicators
AN2 Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of AN2 Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
AN2 Therapeutics time-series forecasting models is one of many AN2 Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary AN2 Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
AN2 Stock media impact
There is far too much social signal, news, headlines, and media speculation about AN2 Therapeutics that are available to investors today. This information is accessible both publicly - through AN2 Therapeutics' media outlets and privately, via word of mouth or internal channels. However, regardless of the source, the sheer volume of AN2-related data is difficult to distill into actionable insights, especially for investors who are not well-versed in the rapidly evolving tools and techniques of investment management.
A primary focus of AN2 Therapeutics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of AN2 Therapeutics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to AN2 Therapeutics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive AN2 Therapeutics alpha.
AN2 Therapeutics Corporate Management
| MBA BS | Chief Officer | Profile | |
| Vince Hernandez | Senior Chemistry | Profile | |
| Eric Easom | CEO, Cofounder | Profile | |
| Michael Alley | CoFounder Biology | Profile | |
| Stephen Prior | Chief Officer | Profile | |
| Paul MD | Chief Officer | Profile |
Already Invested in AN2 Therapeutics?
The danger of trading AN2 Therapeutics is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of AN2 Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than AN2 Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile AN2 Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for AN2 Stock Analysis
When running AN2 Therapeutics' price analysis, check to measure AN2 Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AN2 Therapeutics is operating at the current time. Most of AN2 Therapeutics' value examination focuses on studying past and present price action to predict the probability of AN2 Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AN2 Therapeutics' price. Additionally, you may evaluate how the addition of AN2 Therapeutics to your portfolios can decrease your overall portfolio volatility.